featured
Comparing Switch to Ocrelizumab, Cladribine, or Natalizumab After Fingolimod Treatment Cessation in Patients With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Neurology, Neurosurgery, and Psychiatry
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
J. Neurol. Neurosurg. Psychiatr. 2022 Dec 01;93(12)1330-1337, C Zhu, Z Zhou, I Roos, D Merlo, T Kalincik, S Ozakbas, O Skibina, J Kuhle, S Hodgkinson, C Boz, R Alroughani, J Lechner-Scott, M Barnett, G Izquierdo, A Prat, D Horakova, E Kubala Havrdova, R Macdonell, F Patti, SJ Khoury, M Slee, R Karabudak, M Onofrj, V Van Pesch, J Prevost, M Monif, V Jokubaitis, A van der Walt, H ButzkuevenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.